Tags

Type your tag names separated by a space and hit enter

Emerging topics in pediatric bone and mineral disorders 2008.
Semin Nephrol. 2009 Jul; 29(4):370-8.SN

Abstract

The calcium sensing receptor (CaSR) and fibroblast growth factor 23 (FGF-23) play central roles in the regulation of calcium and phosphorus metabolism, respectively. CaSR controls parathyroid hormone secretion and renal calcium reabsorption. Inactivating mutations of the CaSR result in conditions characterized by hypercalcemia and hypocalciuria, whereas activating lesions cause hypoparathyroidism and hypercalciuria. Calcimimetics are a group of agonists for the CaSR that have been shown to be powerful agents in the treatment of secondary hyperparathyroidism. FGF-23 acts on the kidney to inhibit the reabsorption of phosphate and the synthesis of 1,25(OH)(2)D. Disorders of increased FGF-23 function are associated with hypophosphatemia, inappropriately low 1,25(OH)(2)D levels, and either rickets or osteomalacia. Conversely, decreased FGF-23 activity results in hyperphosphatemia, increased 1,25(OH)(2)D levels, and abnormal soft-tissue calcification. In chronic kidney disease, increases in FGF-23 are being investigated as markers of disease progression.

Authors+Show Affiliations

Department of Pediatrics, Levine Children's Hospital at Carolinas Medical Center, Charlotte, NC 28232-2861, USA. charles.mckay@carolinashealthcare.orgNo affiliation info available

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

19615558

Citation

McKay, Charles P., and Anthony Portale. "Emerging Topics in Pediatric Bone and Mineral Disorders 2008." Seminars in Nephrology, vol. 29, no. 4, 2009, pp. 370-8.
McKay CP, Portale A. Emerging topics in pediatric bone and mineral disorders 2008. Semin Nephrol. 2009;29(4):370-8.
McKay, C. P., & Portale, A. (2009). Emerging topics in pediatric bone and mineral disorders 2008. Seminars in Nephrology, 29(4), 370-8. https://doi.org/10.1016/j.semnephrol.2009.03.020
McKay CP, Portale A. Emerging Topics in Pediatric Bone and Mineral Disorders 2008. Semin Nephrol. 2009;29(4):370-8. PubMed PMID: 19615558.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Emerging topics in pediatric bone and mineral disorders 2008. AU - McKay,Charles P, AU - Portale,Anthony, PY - 2009/7/21/entrez PY - 2009/7/21/pubmed PY - 2009/9/23/medline SP - 370 EP - 8 JF - Seminars in nephrology JO - Semin Nephrol VL - 29 IS - 4 N2 - The calcium sensing receptor (CaSR) and fibroblast growth factor 23 (FGF-23) play central roles in the regulation of calcium and phosphorus metabolism, respectively. CaSR controls parathyroid hormone secretion and renal calcium reabsorption. Inactivating mutations of the CaSR result in conditions characterized by hypercalcemia and hypocalciuria, whereas activating lesions cause hypoparathyroidism and hypercalciuria. Calcimimetics are a group of agonists for the CaSR that have been shown to be powerful agents in the treatment of secondary hyperparathyroidism. FGF-23 acts on the kidney to inhibit the reabsorption of phosphate and the synthesis of 1,25(OH)(2)D. Disorders of increased FGF-23 function are associated with hypophosphatemia, inappropriately low 1,25(OH)(2)D levels, and either rickets or osteomalacia. Conversely, decreased FGF-23 activity results in hyperphosphatemia, increased 1,25(OH)(2)D levels, and abnormal soft-tissue calcification. In chronic kidney disease, increases in FGF-23 are being investigated as markers of disease progression. SN - 1558-4488 UR - https://www.unboundmedicine.com/medline/citation/19615558/Emerging_topics_in_pediatric_bone_and_mineral_disorders_2008_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0270-9295(09)00057-6 DB - PRIME DP - Unbound Medicine ER -